Symvivo

Symvivo is a clinical-stage gene therapy company developing oral DNA vaccines for life-threatening diseases such as COVID-19, with broader therapeutic potential in intravenous treatments for cancer and genetic disorders. Our current projects span clinical and preclinical spaces in oncology, ischemic heart disease, vaccines, and rare diseases.